Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 1.20B | P/E | - | EPS this Y | 61.70% | Ern Qtrly Grth | - |
| Income | -69.24M | Forward P/E | 101.00 | EPS next Y | 129.00% | 50D Avg Chg | 19.00% |
| Sales | 75.77M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 55.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | - |
| Recommedations | 2.20 | Quick Ratio | 1.20 | Shares Outstanding | 131.88M | 52W Low Chg | 127.00% |
| Insider Own | 5.50% | ROA | -28.58% | Shares Float | 99.89M | Beta | 0.83 |
| Inst Own | 83.29% | ROE | - | Shares Shorted/Prior | 11.27M/12.17M | Price | 9.09 |
| Gross Margin | 94.11% | Profit Margin | -91.38% | Avg. Volume | 6,224,763 | Target Price | 10.37 |
| Oper. Margin | -73.54% | Earnings Date | Aug 7 | Volume | 11,420,980 | Change | 0.00% |
About CTI BioPharma Corp.
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Craig Adam R | President and CEO President and CEO | Jan 24 | Sell | 6.01 | 85,317 | 512,755 | 29,440 | 01/26/23 |
| Craig Adam R | President and CEO President and CEO | Jan 24 | Option | 0.84 | 85,317 | 71,666 | 31,557 | 01/26/23 |
| Craig Adam R | President and CEO President and CEO | Dec 29 | Sell | 6.01 | 115,583 | 694,654 | 29,440 | 01/03/23 |
| Craig Adam R | President and CEO President and CEO | Dec 29 | Option | 0.84 | 115,583 | 97,090 | 114,123 | 01/03/23 |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Dec 29 | Sell | 6.01 | 54,042 | 324,792 | 17,127 | 01/03/23 |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Dec 29 | Option | 0.95 | 54,042 | 51,340 | 44,148 | 01/03/23 |
| Metzger Michael A | Director Director | Nov 08 | Option | 0.92 | 91,500 | 84,180 | 91,500 | 11/10/22 |
| Metzger Michael A | Director Director | Nov 08 | Sell | 5.63 | 91,500 | 515,145 | 11/10/22 | |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Jun 30 | Option | 0.95 | 22,592 | 21,462 | 39,505 | 09/20/22 |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Jun 30 | Sell | 6.02 | 22,592 | 136,004 | 16,913 | 09/20/22 |
| BVF PARTNERS L P/IL | - - | Aug 09 | Sell | 6.12 | 8,500,000 | 52,020,000 | 6,148 | 08/11/22 |
| Metzger Michael A | Director Director | Jul 07 | Sell | 6.53 | 20,121 | 131,390 | 07/11/22 | |
| Metzger Michael A | Director Director | Jul 05 | Option | 0.84 | 91,500 | 76,860 | 111,621 | 07/07/22 |
| Metzger Michael A | Director Director | Jul 05 | Sell | 6.1 | 91,500 | 558,150 | 20,121 | 07/07/22 |
| Craig Adam R | President and CEO President and CEO | Jun 30 | Option | 0.84 | 72,223 | 60,667 | 41,084 | 07/06/22 |
| Craig Adam R | President and CEO President and CEO | Jun 30 | Sell | 6.04 | 72,223 | 436,227 | 22,861 | 07/06/22 |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Jun 17 | Option | 2.15 | 60,000 | 129,000 | 57,397 | 06/17/22 |
| KIRSKE DAVID | EVP, Chief Financial.. EVP, Chief Financial Officer | Jun 17 | Sell | 6.13 | 60,000 | 367,800 | 7,397 | 06/17/22 |
| Craig Adam R | President and CEO President and CEO | Jun 01 | Option | 0.84 | 72,223 | 60,667 | 34,901 | 06/03/22 |
| Craig Adam R | President and CEO President and CEO | Jun 01 | Sell | 6 | 72,223 | 433,338 | 16,678 | 06/03/22 |